SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending amid ongoing discussions around U.S. efforts to secure the rare earth supply chain, with community members highlighting the stock's potential for upward recovery. Bullish sentiment centers on MP's existing government and Apple contracts, as well as potential tailwinds from trade negotiations and domestic mining initiatives. However, some traders express concern about market volatility and dependence on developments with China.

Superfruits AI is redefining the Web3 landscape with an ecosystem of fruit-themed AI agents offering specialized insights and services, ranging from blockchain security to market sentiment analysis. Building on this vibrant foundation, we're introducing groundbreaking features like a proprietary Web3-trained AI model, an interactive Virtual Research Room, and the innovative concept of "Juices." These "Juices" empower high token holders to mix and match agents' capabilities, creating custom virtual rooms where agents collaborate on tailored analyses for portfolios or projects. By blending cutting-edge AI with gamified user experiences, Superfruits AI positions itself as a pioneer in Web3 analytics, offering unique tools that not only secure but also enrich the decentralized journey for every user.

SuperFruits AI

SuperFruits AI ($SUPAI) is trending as the community discusses its potential breakout, highlighting the intersection of AI and crypto. Despite some concerns about team activity, many believe $SUPAI is in an accumulation phase, exhibiting controlled chart structure and strength, fueled by a dedicated community.

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in May 2015 and is headquartered in Foster City, CA.

Apollomics Inc - Ordinary Shares - Class A

APLM is trending due to recent volatility and discussions around a potential short squeeze, drawing attention from traders. Community members are actively debating the stock's low float and potential for significant price movement, both upward and downward, with some expressing skepticism. The stock's past performance and upcoming company events are also contributing to the ongoing conversation.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz is trending as traders discuss upcoming earnings and potential for a short squeeze, with some pointing to high short interest and a low float. The community is also buzzing about the company's partnership with Amazon for online car sales. Overall, there's a mixed sentiment around Hertz's prospects, with some highlighting debt concerns while others focus on potential catalysts for a price increase.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma ($XPL) is generating mixed reactions, with some users labeling it "trash" and a "scam," while others see potential for future value and are buying the dip. Community discussion revolves around its recent price drop, comparisons to other cryptocurrencies, and speculation about potential catalysts like listings on Chinese exchanges or backing from Tether. Concerns are being raised regarding the token's launch, constant selling pressure, and overall performance.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to its low float and recent breakout, sparking excitement among traders looking for a potential squeeze. Community members are discussing the possibility of a significant run, with some eyeing price targets in the double digits. The stock's chart and momentum are attracting attention, leading to increased watchlists and speculation about a parabolic move.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate upcoming earnings, with community discussions focused on whether the company can justify its high valuation and potential for a stock split. Bulls cite recent partnerships and AI advancements as reasons for optimism, while bears express concerns about market sentiment and potential pullbacks. Some traders are closely watching options activity and technical indicators for clues about the stock's next move.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTERION is trending amidst discussions of potential market manipulation, with some traders accusing CZ of "pump and dump" schemes. The community is actively debating holding strategies and liquidation levels, while also speculating on the future value. Additionally, the coin is mentioned in the context of broader discussions around DEXs and potential competition with Hyperliquid.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a recent lawsuit filed by Aurinia against a former FDA official, alleging bribery and defamation, which has sparked outrage among retail traders who suspect stock manipulation. The community is actively discussing the potential impact of this legal action on the company's future prospects, including buyout possibilities and the removal of a black box warning on their drug LUPKYNIS. Investors are also calling for accountability and expressing frustration with the company's management in light of these events.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

CSIQ is trending as the community discusses potential short squeeze setups and positive developments in its China-based subsidiary. Bullish sentiment is fueled by rising solar sector interest and the possibility of significant contracts, with some seeing the stock as undervalued relative to peers. Discussions also include potential sale of Recurrent Energy and its impact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?

NewAmsterdam Pharma Company N.V. (NAMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a...

Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

<p>Corcept Therapeutics shares&nbsp;fell 0.9% in premarket trading Monday&nbsp;despite the company reporting late-breaking Phase 3 data showing its drug relacorilant improved outcomes in patients with platinum-resistant ovarian cancer, including those who had previously taken PARP inhibitors.</p><h2 class="st-heading-2"><strong>Relacorilant Improves Survival In Difficult-To-Treat Patients</strong></h2><p>The new results came from the late-stage ROSELLA trial, which tested relacorilant alongside nab-paclitaxel chemotherapy. Patients who had already stopped responding to PARP inhibitor treatment saw a 40% lower risk of their cancer worsening or leading to death when given the combination compared with chemotherapy alone. Median progression-free survival was 7.36 months in both PARP-experienced subgroups, according to the company.</p><p>Relacorilant works by blocking cortisol’s effects, which can promote tumor growth and resistance to chemotherapy. The company said the therapy was well tolerated, with adverse events comparable to standard chemotherapy. Corcept noted that relacorilant achieved its benefit without adding to patients’ safety burden.</p><h2 class="st-heading-2"><strong>Broader Trial Expansion Underway</strong></h2><p>Corcept also announced an expansion of its Phase 2 BELLA trial to include three study arms, which include platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, and endometrial cancer. Early data from these studies are expected in late 2026.</p><p>Chief Development Officer Bill Guyer said the new results strengthen confidence in relacorilant’s potential, adding that the FDA’s recent acceptance of the company’s New Drug Application (NDA) for platinum-resistant ovarian cancer brings Corcept “closer than ever” to delivering a new treatment option.</p><h2 class="st-heading-2"><strong>Regulatory Path&nbsp;</strong></h2><p>The FDA has set a July 11, 2026, PDUFA date for relacorilant in platinum-resistant ovarian cancer and a Dec. 30 date for its hypercortisolism indication. The company has also filed for European approval.</p><h2 class="st-heading-2"><strong>Stocktwits Users Turn Bullish As Corcept Bounces Off Support</strong></h2><p>On Stocktwits, retail sentiment for Corcept Therapeutics was ‘bullish’ amid ‘high’ message volume.</p><p>One user said they saw the update as a sign of renewed investor optimism and planned to keep holding their shares.</p><p><stembedurl>https://stocktwits.com/TheAlmani/message/632887580</stembedurl></p><p>Another pointed to a technical rebound in the stock, saying they were averaging down after what they viewed as a bounce off support.</p><p><stembedurl>https://stocktwits.com/Silent_Raven6450/message/632899741</stembedurl></p><p><a href="https://stocktwits.com/symbol/CORT">Corcept’s stock</a> has risen 56% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Corcept’s stock (CORT) has risen 56% so far in 2025. | Image source: Getty Images

 Corcept Therapeutics Stock Slips Premarket Despite Strong Cancer Trial Data Showing 40% Drop In Disease Progression Risk

Phase 3 ROSELLA trial showed relacorilant plus chemotherapy helped patients with platinum-resistant ovarian cancer live longer without disease worsening, including those who failed prior PARP inhibitor treatment.

Equity

The Phase 3 ROSELLA trial showed relacorilant plus chemotherapy helped patients with platinum-resistant ovarian cancer live longer without disease worsening, including those who failed prior PARP inhibitor treatment.

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer

Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?

Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.

FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.

Can Korlym Drive Corcept's Growth Through the Rest of 2025?

CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.13	--	--	N/A
Q2 '25	$0.19	$0.29	54.67%	BEAT
Q1 '25	$0.14	$0.17	19.30%	BEAT
Q4 '24	$0.43	$0.26	-39.00%	MISSED
Q3 '24	$0.28	$0.41	45.42%	BEAT

CORT
Corcept Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest CORT News

CORTCorcept Therapeutics Inc